161 related articles for article (PubMed ID: 17176359)
1. Carvedilol accelerate elevation of serum potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate or candesartan cilexetil.
Saito M; Nakayama D; Takada M; Hirooka K; Yasumura Y
J Clin Pharm Ther; 2006 Dec; 31(6):535-40. PubMed ID: 17176359
[TBL] [Abstract][Full Text] [Related]
2. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
Saito M; Takada M; Hirooka K; Isobe F; Yasumura Y
J Clin Pharm Ther; 2005 Dec; 30(6):603-10. PubMed ID: 16336294
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
Weir RA; McMurray JJ; Puu M; Solomon SD; Olofsson B; Granger CB; Yusuf S; Michelson EL; Swedberg K; Pfeffer MA;
Eur J Heart Fail; 2008 Feb; 10(2):157-63. PubMed ID: 18242128
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
5. Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN).
Komajda M; Lutiger B; Madeira H; Thygesen K; Bobbio M; Hildebrandt P; Jaarsma W; Riegger G; Rydén L; Scherhag A; Soler-Soler J; Remme WJ;
Eur J Heart Fail; 2004 Jun; 6(4):467-75. PubMed ID: 15182773
[TBL] [Abstract][Full Text] [Related]
6. Effects of an ACE inhibitor or angiotensin receptor blocker on potassium in CAPD patients.
Phakdeekitcharoen B; Leelasa-nguan P
Am J Kidney Dis; 2004 Oct; 44(4):738-46. PubMed ID: 15384026
[TBL] [Abstract][Full Text] [Related]
7. Life-threatening hyperkalemia during a combined therapy with the angiotensin receptor blocker candesartan and spironolactone.
Fujii H; Nakahama H; Yoshihara F; Nakamura S; Inenaga T; Kawano Y
Kobe J Med Sci; 2005; 51(1-2):1-6. PubMed ID: 16199929
[TBL] [Abstract][Full Text] [Related]
8. Effects of enalapril, candesartan or both on neurohumoral activation and LV volumes and function in patients with heart failure not treated with a beta-blocker.
White M; Rouleau JL; Afzal R; Floras J; Yusuf S; McKelvie RS
Ther Adv Cardiovasc Dis; 2009 Apr; 3(2):113-21. PubMed ID: 19299427
[TBL] [Abstract][Full Text] [Related]
9. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects.
Licata G; Di Pasquale P; Parrinello G; Cardinale A; Scandurra A; Follone G; Argano C; Tuttolomondo A; Paterna S
Am Heart J; 2003 Mar; 145(3):459-66. PubMed ID: 12660669
[TBL] [Abstract][Full Text] [Related]
10. Are beta-blockers needed in patients receiving spironolactone for severe chronic heart failure? An analysis of the COPERNICUS study.
Krum H; Mohacsi P; Katus HA; Tendera M; Rouleau JL; Fowler MB; Coats AJ; Roecker EB; Packer M;
Am Heart J; 2006 Jan; 151(1):55-61. PubMed ID: 16368292
[TBL] [Abstract][Full Text] [Related]
11. Beta-receptor selectivity of carvedilol and metoprolol succinate in patients with heart failure (SELECT trial): a randomized dose-ranging trial.
Zebrack JS; Munger M; Macgregor J; Lombardi WL; Stoddard GP; Gilbert EM
Pharmacotherapy; 2009 Aug; 29(8):883-90. PubMed ID: 19637941
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]).
Am J Cardiol; 1996 Oct; 78(8):902-7. PubMed ID: 8888663
[TBL] [Abstract][Full Text] [Related]
13. Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program.
Desai AS; Swedberg K; McMurray JJ; Granger CB; Yusuf S; Young JB; Dunlap ME; Solomon SD; Hainer JW; Olofsson B; Michelson EL; Pfeffer MA;
J Am Coll Cardiol; 2007 Nov; 50(20):1959-66. PubMed ID: 17996561
[TBL] [Abstract][Full Text] [Related]
14. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
[TBL] [Abstract][Full Text] [Related]
15. Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neurohormones, and clinical symptoms in patients with congestive heart failure.
Mitrovic V; Willenbrock R; Miric M; Seferovic P; Spinar J; Dabrowski M; Kiowski W; Marks DS; Alegria E; Dukát A; Lenz K; Arens HA
Am Heart J; 2003 Mar; 145(3):E14. PubMed ID: 12660683
[TBL] [Abstract][Full Text] [Related]
16. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
Young JB; Dunlap ME; Pfeffer MA; Probstfield JL; Cohen-Solal A; Dietz R; Granger CB; Hradec J; Kuch J; McKelvie RS; McMurray JJ; Michelson EL; Olofsson B; Ostergren J; Held P; Solomon SD; Yusuf S; Swedberg K;
Circulation; 2004 Oct; 110(17):2618-26. PubMed ID: 15492298
[TBL] [Abstract][Full Text] [Related]
17. Additive effects of spironolactone and candesartan on cardiac sympathetic nerve activity and left ventricular remodeling in patients with congestive heart failure.
Kasama S; Toyama T; Sumino H; Matsumoto N; Sato Y; Kumakura H; Takayama Y; Ichikawa S; Suzuki T; Kurabayashi M
J Nucl Med; 2007 Dec; 48(12):1993-2000. PubMed ID: 18006623
[TBL] [Abstract][Full Text] [Related]
18. Appropriateness and complications of the use of spironolactone in patients treated in a heart failure clinic.
Goland S; Naugolny V; Korbut Z; Rozen I; Caspi A; Malnick S
Eur J Intern Med; 2011 Aug; 22(4):424-7. PubMed ID: 21767763
[TBL] [Abstract][Full Text] [Related]
19. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as a bolus, in refractory congestive heart failure.
Paterna S; Di Pasquale P; Parrinello G; Amato P; Cardinale A; Follone G; Giubilato A; Licata G
Eur J Heart Fail; 2000 Sep; 2(3):305-13. PubMed ID: 10938493
[TBL] [Abstract][Full Text] [Related]
20. The influence of enalapril and spironolactone on electrolyte concentrations in Doberman pinschers with dilated cardiomyopathy.
Thomason JD; Rapoport G; Fallaw T; Calvert CA
Vet J; 2014 Dec; 202(3):573-7. PubMed ID: 25257351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]